# A Master Protocol Study to Investigate Biomarker-guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy in Participants With Advanced/Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct07060365/  
OnCo record `nct07060365` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is withdrawn.

## Summary

The registry lists NCT07060365 as withdrawn, last updated 2026-04-03. Enrolment is 0 actual participants. Interventions: Saruparib. Primary measures include Number of participants with treatment-emergent adverse event (TEAEs), serious adverse events (SAEs), and adverse events (AEs) leading to discontinuation. The registry reason for stopping is: The study termination is based on Sponsor decision and is not related to any safety, efficacy or quality concerns. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-10-06
- Registry id: NCT07060365
- Phase: 1/2
- Setting: A Master Protocol Phase I/II Study to Investigate Biomarker-Guided Novel Anticancer Agent(s) as Monotherapy or Combination Therapy for the Treatment of Participants With Advanced/Recurrent Ovarian Cancer (Ovarian Platform)
- Sponsor: AstraZeneca
- Enrolled: 0

## Sources

- ClinicalTrials.gov NCT07060365: https://clinicaltrials.gov/study/NCT07060365

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [Saruparib](https://onco.cc/drugs/saruparib/)

---
JSON: https://onco.cc/api/v1/entities/nct07060365.json